

# SURVIVIX




Adjuvant therapy for  
improving survival in  
sepsis  
*(bacterial and viral)*

SurvivX B.V.  
Leonie de Best  
Co-founder and CBO


Investors Forum, Dutch  
Life Sciences conference

# Sepsis:

**Life-threatening organ dysfunction by a dysregulated host-response to infections**



Any type of infection can lead to sepsis  
**Increasing risk due to viral pandemics, AMR, aging, chronic disease etc.**



Immune overreaction followed by **immune suppression**



**No solutions** for this last and **most fatal stage**


# The severity of sepsis



Annual global incidence  
~0,6%  
**It can happen to anyone**



**2 out of 5 cases**  
are **children <5 years**



Fatality rate ~**20%**  
~**11M WW** annually  
**50%** of survivors suffer  
from **long term effects**




**#1 cost** of hospitalization in USA  
**>\$27 billion** annually

# Our solution: Inspired by nature, empirical finding from India



**Protection** against sepsis by a mosquito transferred round-worm parasite



Prevalence of **parasite**:  
**42%** in healthy controls  
**7%** with **sepsis** on ICU

## A worm parasite can protect human for (severe) sepsis

# Our solution: the protein



## Immune modulatory

### Worm-protein identified

Activation of NF- $\kappa$ B and AP-1 mediated signalling in TLR2 and TLR4 reporter cells



## Recombinant

production possible

World-wide **exclusive license** on IP from **C-CAMP, India**



## Improved survival in

mice in 2 validated sepsis models, especially in **late-stage sepsis**

## In-vitro and in-vivo evidence

# Current status



**Seed investment  
(CL) by OostNL  
€350K**

June 2023



**Part of INCATE Incubator  
community**

**Non-dilutive investment  
potential**

Sept 2023



**Together with KOLs:  
Early verification of MOA  
Ex-vivo human POC to show  
immune recovery potential**

2023–2024

# A collaborative team in the Netherlands and India

SurvivX\Europe



**Co-founder & CBO**

Leonie de Best

- Analytical chemist
- > 20 years expertise in pharmaceutical and diagnostic product development
- > 10 years of executive management positions



**Co-founder & CEO**

Remko van Leeuwen

- Physician
- Extensive experience in infectious diseases
- > 30 years experience in preclinical and clinical development of vaccines and therapeutics

C-CAMP India



**Scientific Advisor**

Prof. Ravindran

- Inventor of IP
- Scientific collaborator



**Scientific Advisor**

Dr. Taslimarif Saiyed

- Inventor of IP
- Scientific collaborator

# Dutch academic partners involved in PoC studies



**Prof. Peter Pickkers**  
Experimental  
Intensive care medicine



**Dr. Matthijs Kox**  
Intensive care  
research




**Prof. Tom vd Poll**  
Internal Medicine &  
Infectious Diseases

**Radboudumc**

 **Amsterdam UMC**  
Universitair Medische Centra



# Development roadmap and financial plan




Extended verification  
of **MOA,**  
**Production Tech**  
**Transfer**

2024-2025  
€6M



DP development  
**GMP production**  
**IND readiness**

2025-2026



**Phase I and IIa safety**  
and efficacy  
**clinical trials**

2026-2028



**Out licensing to**  
large pharma

**Do you want to join us  
to reduce the casualties and  
burden of sepsis?**

**Please connect via:**

**[Leonie.debest@survivx.com](mailto:Leonie.debest@survivx.com)**

**[Remko.vanleeuwen@survivx.com](mailto:Remko.vanleeuwen@survivx.com)**


# Questions?

# SURVIVX



Survivx.com  
info@survivx.com  
+31 412 711 261


## Face the facts



~**30%** of patients at **ICU** have sepsis



Silent pandemic of **AMR** is **reality today**, next (**viral**) pandemic is a matter of **time**



Susceptibility increases due to **aging**, **rise of chronic disease** and **immune compromised patients**


**We already have a problem, and more is coming**

# Sepsis: a heterogeneous disease

## Urgent need for new approach to sepsis treatment



Replace outdated  
**One-size-fits all**  
approach




**Biomarker based**  
**personalized**  
treatment



**Rapid identification of**  
patients that suffer from  
**immune suppression**

## Companion biomarker identification is crucial

# We need to act now



**Casualties of sepsis and related healthcare cost must decrease**



**World's leading scientists and physicians involved**



**We need to be prepared for the increase of infections and sepsis**

**Join us to reduce casualties of sepsis!**